Omalizumab

The nation's largest network of food allergy clinics will open four Southern California clinics and fill a void for local comprehensive food allergy care LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- Latitude Food Allergy Care, the leading network of food allergy clinics in the United States, today announced an affiliation with Children's Hospital Los Angeles (CHLA) to bring specialized food allergy treatment to Southern California families. As part of this affiliation, Latitude has just opened its first Los Angeles clinic in Westwood, which is now open to patients of all ages. Three additional locations are planned across Southern California over the next year. This affiliation also gives children and young adults, access to the multidisciplinary team of specialists at the Gore Family Allergy Center at CHLA. Food allergies continue to surge across the United States, with approximately 32 million Americans living with food allergies, including 5.6 million children. In the Los Angeles metropolitan area alone, thousands of people are navigating food allergies, yet access to treatment remains severely limited. This affiliation addresses the urgent need for pediatric food allergy care in Los Angeles, where high demand, waiting lists, and limited specialized treatment options like oral immunotherapy (OIT) and Xolair have restricted access for many families. "Children's Hospital Los Angeles is home to the Gores Family Allergy Center and provides comprehensive care for children with food allergies, asthma, and other allergic and immunologic conditions throughout Southern California," said Matthew Keefer, M.D., CEO of the Children's Hospital Los Angeles Medical Group. "This affiliation enables Children's Hospital Los Angeles to expand its footprint in food allergy care and extend services to more patients across the region." The affiliation between Latitude and CHLA includes: Immediate Patient Access: CHLA can now refer patients to Latitude for specialized food allergy treatments, reducing wait times for families seeking comprehensive care. Enhanced Treatment Options: Access to OIT and Xolair treatments provided in-clinic. Potential Research Collaboration: Similar to Latitude's successful research partnership with Weill Cornell Medicine in New York, the CHLA affiliation may expand to include joint research initiatives to advance food allergy treatment and outcomes. Training and Education: The affiliation enables both organizations to share expertise and advance the standard of care for food allergy treatment in Southern California and beyond. Collaborative Medical Care: Latitude allergists and CHLA pediatricians will work together as a unified care team for each patient. With an expanding network of clinics from San Francisco to New York, Latitude has treated thousands of patients, many of whom are now able to safely eat foods they previously avoided entirely. The company's evidence-based approach and board-certified allergist-led care model has established it as the premier destination for food allergy treatment on both coasts. "Bringing Latitude Food Allergy Care to Southern California enables us to bring treatment to a significantly underserved market, ensuring families receive timely, comprehensive food allergy care," said Kimberley Yates, co-founder and CEO of Latitude Food Allergy Care. "At Latitude, our patients can access testing for all foods and then be treated simultaneously for multiple food allergies." With the upcoming back-to-school season, the opening of Latitude's first West Los Angeles clinic is especially timely. Food allergies pose a major concern in new school settings and extracurricular activities, heightened by increased peer interactions. The new referral pipeline allows CHLA allergists, LA-area allergists, and pediatricians to refer patients directly to Latitude for specialized treatments not widely available in the region. This ensures children with food allergies can have the support they need as they return to school and navigate shared spaces and cafeterias. Ninety-two percent of Latitude patients of any age who undergo OIT at Latitude successfully reach maintenance, meaning they are desensitized to their allergens. That number is even higher for patients under four (clinics can even treat babies) — Latitude's success rate is 97 percent for its youngest patients. Dr. Akansha Ganju, a board-certified allergist and immunologist, will lead Latitude's new Westwood clinic. Dr. Ganju returns to Los Angeles after completing her fellowship at UCLA and brings extensive experience in food allergy treatment and oral immunotherapy. Her appointment represents a homecoming to the city where she trained and developed her expertise in food allergy care. Latitude accepts most PPO insurance plans. To book an appointment, email [email protected] or call (888) 528-1592. For more information about Latitude Food Allergy Care, visit latitudefoodallergycare.com. About Latitude Food Allergy Care Latitude Food Allergy Care is the leading network of clinics dedicated to treating food allergies. Led by board-certified allergists, Latitude redefines care through advanced diagnostics, evidence-based approaches such as OIT, and personalized treatment plans. Learn more at latitudefoodallergycare.com and follow Latitude on Instagram, Facebook, and Linkedin. SOURCE Latitude Food Allergy Care WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

药械追踪 No.1 / 百济神州2025Q2财报：收入13亿美元，百悦泽收入增长49% 2025年8月6日，百济神州（Nasdaq：ONC；6160.HK；688235.SH）公布2025年第二季度财务业绩及业务进展。报告期内，公司总收入达13亿美元，同比增长42%，总收入增长主要得益于百悦泽（泽布替尼）在美国和欧洲的销售额增长。泽布替尼全球收入达9.5亿美元，同比增长49%。 2025年第二季度，公司产品收入为13亿美元，上年同期为9.21亿美元。产品收入增长主要得益于百悦泽销售额增长。美国仍是公司最大的市场，产品收入达6.85亿美元，上年同期为4.79亿美元。从安进公司获得授权许可的产品和百泽安（替雷利珠单抗）的销售也对产品收入增长做出贡献。 2025年上半年，公司收入175.18亿元（人民币），同比增长46%；产品收入173.60亿元，同比增长45.8%。2025年半年度，百悦泽全球销售额总计125.27亿元，同比增长56.2%，在血液肿瘤领域进一步巩固领导地位。其中，美国销售额总计89.58亿元，同比增长51.7%，主要得益于该产品在所有适应证领域强劲的需求增长，以及净定价带来的适度利好；欧洲销售额总计19.18亿元，同比增长81.4%，主要得益于该产品在所有欧洲主要市场的市场份额提升，其中包括德国、意大利、西班牙、法国和英国；中国销售额总计11.92亿元，同比增长36.5%，主要得益于该产品在已获批适应证领域的销售增长。 2025年半年度，百泽安的销售额总计26.43亿元，同比增长20.6%。百泽安销售额的增长，主要得益于该产品在中国获批新适应证纳入医保所带来的新增患者需求以及药品进院数量的增加。百泽安在中国PD-1市场取得领先的市场份额。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 阿斯利康本瑞利珠单抗在华获批新适应证 2025年8月7日，阿斯利康（LSE/STO/Nasdaq: AZN）宣布，其在中国的首个呼吸生物制剂凡舒卓（英文商品名：Fasenra，通用名：本瑞利珠单抗注射液）新适应证在中国正式批准，用于儿童（6至＜12岁）重度嗜酸粒细胞性哮喘（SEA）的维持治疗。 此次批准是基于全球多中心、开放标签的TATE Ⅲ期临床试验的积极结果。在该临床试验中，本瑞利珠单抗达到了主要研究终点，显示其在6-11岁SEA儿童中，具有良好的药代动力、药效特征与安全性，与青少年及成人研究结果一致，支持其在儿童群体中使用。本瑞利珠单抗采用皮下注射方式，前三次每4周注射一次，之后每8周注射一次。 本瑞利珠单抗是精准靶向嗜酸性粒细胞的抗IL-5R生物制剂，此前已在中国获批用于成人和12岁及以上青少年SEA的维持治疗。该适应证已在美国、欧盟、日本等80多个国家和地区获批上市，6-11岁儿童SEA适应证也已在美国和日本获批。 ->点击文末阅读原文，解锁完整双语新闻 企业动态 No.1 / 诺华拟收购Avidity Biosciences，强化罕见病管线布局 2025年8月6日，多家媒体援引知情人士消息称，诺华（NYSE: NVS）正评估收购Avidity Biosciences（NASDAQ: RNA），后者专注于罕见遗传疾病领域的治疗开发，目前市值约58亿美元。受消息影响，Avidity股价当日飙升26%，其竞争对手Dyne Therapeutics（NASDAQ: DYN）股价亦上涨7.5%。 交易谈判仍处于早期阶段，存在不确定性，双方均拒绝对收购事宜发表评论。Avidity正在与顾问评估潜在战略选择。 Avidity目前有三款肌营养不良相关药物处于临床阶段，最早或于2027年获批。其中核心产品del-zota用于治疗杜氏肌营养不良（DMD）外显子44跳变患者已获FDA授予加速批准通道，目前正处于II期试验阶段。 此次潜在交易是诺华2025年收购策略的一部分，意在充实其罕见病管线，缓解旗下核心产品（如诺欣妥、茁乐、可善挺）面临的专利悬崖压力。此前诺华已先后收购Anthos Therapeutics（31亿美元）、Regulus Therapeutics（最多17亿美元）并与Matchpoint Therapeutics达成高达10亿美元的合作协议。 ->点击文末阅读原文，解锁完整双语新闻 行业政策 No.1 / 国家医保局发布第十一批药品集采医疗机构报量政策问答 近日，国家医保局发布第十一批药品集采医疗机构报量政策问答。医保局指出，本次集采医疗机构可根据实际需求自主选择按品种报量或按厂牌报量，也可以部分需求量按品种报、部分需求量按厂牌报。如果选择按厂牌报量，不限制具体厂牌数量。若填报的厂牌中选，则该厂牌直接成为医疗机构的供应企业，需完成相应协议量；若没有中选，则该厂牌的报量会由所在省份的主供企业供应。 要求医疗机构报量达到历史采购量的80%；如果存在特殊情况，比如本次集采个别品种为限适应证报量，或者医疗机构以往历史量存在临时性采购等因素，允许医疗机构在近两年平均采购量80%的基础上适当减少报量，并同步提交相关说明。 每个品种可报量的规格均为过评规格，对于未过评规格的需求量，一般情况下，由医疗机构按含量折算计入过评规格的需求量。本次集采中有部分品种存在儿童和成人共用品规；如存在儿童适宜品规未过一致性评价，医疗机构认为无法折算给其他品规，应在报量中说明。如果儿童适宜品规已过评，则正常报量即可。 本次遴选纳入集采范围的均为参比制剂+过评企业数合计达到7家的品种。目前遴选工作已经完成，实际投标企业数量最终少于7家的，集采仍会正常进行。没有参与的企业如果后续有意愿参加集采，按规则也是允许的。 集采协议量一般为医疗机构报量的60%-80%，剩余用量由医疗机构自主选择采购中选或非中选药品。鼓励医保定点民营医疗机构、零售药店参加集采报量，共享集采改革成果。 ->点击阅读原文，解锁完整双语新闻 No.2 / 上海多部门发文促进生物医药产业商业健康险发展 2025年8月6日，国家金融监督管理总局上海监管局、上海市医疗保障局、中共上海市委金融委员会办公室、上海市发展和改革委员会、上海市科学技术委员会、上海市卫生健康委员会和上海市浦东新区人民政府7部门联合发布《关于促进商业健康保险高质量发展助力生物医药产业创新的若干措施》的通知，多维度促进生物医药产业商业健康险发展。 拓宽商业健康保险保障内容，将供需适配的医疗新技术、新药品、新器械、新耗材应用纳入保障范围；丰富商业健康保险产品形式，继续做优做强“沪惠保”，在基础数据支撑基础上，支持将创新药械纳入保障，提高参保人群覆盖面；加快发展商业护理保险，积极参与构建长期照护体系，支持养老服务产业发展。 拓宽商业健康保险服务人群，将老年人、既往症和慢性病人群纳入保障范围。延伸商业健康保险服务领域，探索保险机构与药企形成集体采购药价谈判、新药上市沟通、按疗效付费、分期支付等机制，提升创新药械的可及性和可负担性；鼓励保险机构与医疗机构、体检机构、康复护理机构、签约家庭医生等开展合作；积极参与政府财政支持的健康卫生项目。 鼓励商业健康保险创新实践，持续深化医保个人账户历年结余资金购买商业健康保险项目，推动商业健康保险与基本医保共同发展、互为补充。鼓励开发由用人单位统一投保且单位缴费比例不低于一定比例、覆盖创新药械费用保障、与基本医保同步结算的团体健康保险产品。加强对创新型商业健康保险业务的合规性监管，防止以政策套利为目的的“伪创新”“乱创新”。 加大政策支持力度。探索建立医保支付、商保赔付、慈善组织参与、药企主动分担等多元支付和多方协同机制，对商业健康保险创新药目录内药品，不计入基本医保自费率指标和集采中选可替代品种监测的范围；探索推进国际医疗跨境收付费模式。 ->点击阅读原文，解锁完整双语新闻 全球医疗情报领导者 解锁隐藏在数据中的商业潜力  关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。 联系我们 投稿 | 发稿 | 媒体合作 ▶ olivia.xu@generalbiologic.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写 点击阅读原文，解锁完整双语新闻